Developer docs
API playgroundTry for free, no card

Search company profiles

XWPharma

Full company profile

uuid0000qt5

Namestring
XWPharma
Legal namestring
XWPharma Ltd.
Websiteurl
xwpharma.com
Company typeenum
Private
Founded yearint
2014
Descriptiontext

XWPharma is a clinical-stage biopharmaceutical company founded in 2014 that develops new chemical entities (NCEs) targeting central nervous system disorders, with a focus on sleep and neuropsychiatric conditions. The company applies a proprietary medicinal chemistry platform centered on time-regulated neurobiology to design orally bioavailable, once-daily or once-nightly therapies that aim to retain the efficacy of validated mechanisms while addressing the tolerability, dosing, or formulation limitations of existing treatments. Its clinical pipeline includes valiloxybate (XW10172), an internally discovered GABAB agonist conjugate of oxybate being developed for narcolepsy and sleep disorders in Parkinson's disease (FDA Orphan Drug Designation granted in 2019), and XW10508, an oral once-daily glutamatergic NMDA antagonist/AMPA activator derived from esketamine for treatment-resistant major depressive disorder and chronic pain. XWPharma operates leanly from a Redwood City, California headquarters with additional offices in Wuhan, China and New Taipei City, Taiwan, and has raised approximately $80.5 million across three venture rounds from investors including KPCB China, Elements Capital, WI Harper, Panacea Venture, J&J Innovation, and WuXi AppTec.

XWPharma's business model is a clinical-stage licensing model: it discovers and develops drug candidates through early clinical milestones, then out-licenses global development and commercialization rights to pharmaceutical partners in exchange for upfront payments, development and sales milestones, and tiered royalties. The company does not maintain a commercial sales force, and its revenue is structurally tied to licensing economics rather than product sales. In September 2025, XWPharma executed its most significant commercial transaction to date — an exclusive global license to Avadel Pharmaceuticals for valiloxybate, generating a $20 million upfront payment plus up to $185 million in potential milestones and tiered royalties on net sales. Prior to this, the company had been funded exclusively through venture capital. Its customer base is therefore enterprise pharmaceutical partners rather than end patients, prescribers, or payers.

Short descriptiontext

XWPharma is a clinical-stage biopharmaceutical company developing orally bioavailable new chemical entities for sleep and neuropsychiatric CNS disorders, including valiloxybate for narcolepsy and XW10508 for depression and chronic pain, monetizing through licensing deals with pharmaceutical partners.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersRedwood City, United States
HQ citystring
Redwood City
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
clinical-stage biopharmaceutical, CNS drug discovery, neurology therapeutics pipeline, new chemical entities, pharmaceutical licensing deals
Industry2 codes
PRIMARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
NAICS code1 code
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Clinical-stage CNS biopharmaceuticals
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Licensing and milestone payments
TypeLicensing Royalties
Description

XWPharma generates revenue through licensing agreements where partners develop and commercialize its drug candidates. The company receives upfront payments, development milestones, performance-based sales milestones, and tiered royalties. For valiloxybate, Avadel paid $20M upfront with potential for up to $30M in development milestones, up to $155M in sales milestones for net sales up to $750M, plus royalties.

stocktitan.net
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

XWPharma is a clinical-stage biopharmaceutical company that internally discovers and develops novel small-molecule new chemical entities (NCEs) for central nervous system (CNS) disorders, including Valiloxybate/XW10172 (a GABAB agonist for narcolepsy and Parkinson's disease sleep disorders) and XW10508 (an orally bioavailable NMDA antagonist/AMPA activator for treatment-resistant major depressive disorder and chronic pain). The company advances these programs through early clinical development and licenses them to large pharmaceutical partners (e.g., Avadel Pharmaceuticals) for late-stage development, regulatory approval, and commercialization in exchange for upfront payments, milestones, and royalties.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

XWPharma is a clinical-stage biopharmaceutical company developing a pipeline of novel CNS drug candidates. The company operates a multi-product portfolio approach with two internally discovered new chemical entities: XW10172 (GABAB agonist for narcolepsy and Parkinson's disease sleep disorders) and XW10508 (NMDA antagonist/AMPA activator for depression and chronic pain). A third candidate, Valiloxybate, was licensed to Avadel Pharmaceuticals in September 2025. All therapies apply novel platform chemistry to time-regulated neurobiology.

Product and service2 records
1Valiloxybate (XW10172 / XWL-008)
CategoryDrug Candidate — GABAB agonist NCE for CNS disorders
Description

Internally discovered, investigational GABAB agonist new chemical entity (NCE) developed for the treatment of narcolepsy and non-motor symptoms (sleep disorders) in Parkinson's disease. Valiloxybate is a novel, patented conjugate of oxybate designed for once-at-bedtime dosing with optimal pharmacokinetics — rapid oral absorption, prompt release, and sustained duration at desired plasma concentrations. It is salt-free and artificial sweetener-free, addressing formulation limitations of existing oxybate therapies. Granted FDA Orphan Drug Designation in June 2019 for narcolepsy.

2XW10508
CategoryDrug Candidate — Glutamatergic NMDA antagonist/AMPA activator NCE
Description

Internally discovered, investigational, orally bioavailable, once-daily glutamatergic new chemical entity providing NMDA receptor inhibition and AMPA receptor activation. Derived from esketamine with extended-release oral formulation, designed to deliver esketamine-like efficacy for treatment-resistant major depressive disorder (MDD) and chronic pain without the transient side effects and administration burden of intranasal or IV esketamine/ketamine.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2025-09-03
Description

Exclusive global license agreement where Avadel obtained rights to develop and commercialize valiloxybate, a once-at-bedtime, salt-free and artificial sweetener-free oxybate therapy for treating narcolepsy and idiopathic hypersomnia. XWPharma received $20 million upfront payment with potential development milestones up to $30 million, performance-based sales milestones up to $155 million for net sales up to $750 million, and tiered royalties.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Markets Xywav (oxybate) and other narcolepsy therapies, generating the bulk of the ~$2B U.S. GABAB narcolepsy market. Directly competes with XWPharma's valiloxybate on mechanism (GABAB agonism) and indication (narcolepsy).

TypeDirect peer
Description

Exclusive global licensee of XWPharma's valiloxybate (September 2025) and developer of Lumryz, an oxybate therapy for narcolepsy. Directly comparable as a narcolepsy-focused commercial-stage peer with overlapping GABAB asset and patient population.

TypeDirect peer
Description

Markets Wakix (pitolisant) for narcolepsy and is expanding its CNS pipeline. Comparable as a CNS-focused, U.S.-based biopharma targeting narcolepsy patients — the same primary indication as XWPharma's lead asset.

TypeDirect peer
Description

Commercial CNS company behind Auvelity for major depressive disorder. Closely comparable to XWPharma's XW10508 in target indication (MDD) and strategy of developing differentiated, mechanism-validated CNS therapies.

TypeDirect peer
Description

CNS-focused biopharma that developed Zurzuvae for postpartum depression and has additional CNS programs. Comparable in focus on CNS indications with high unmet need and use of differentiated neuroactive mechanisms, similar to XWPharma's platform approach.

TypeDirect peer
Description

Develops and commercializes Caplyta for CNS indications including schizophrenia and bipolar depression. Directly comparable as a CNS biopharma addressing neuropsychiatric disorders, now operating under Johnson & Johnson following acquisition.

TypeDirect peer
Description

Markets Nuplazid for Parkinson's disease psychosis and is expanding CNS indications. Directly comparable to XWPharma in CNS focus and overlap on Parkinson's-related indications (XWPharma targets sleep disorders in Parkinson's).

TypeDirect peer
Description

Clinical-stage CNS biopharma developing therapies for agitation in dementia and other neuropsychiatric conditions. Comparable as a small, clinical-stage CNS peer pursuing differentiated mechanisms in underserved indications.

TypeBroad incumbent
Description

Markets Spravato (esketamine) for treatment-resistant depression, directly competing with XWPharma's XW10508. As a diversified pharma incumbent, J&J is a broader peer but the most relevant comparator for XW10508's NMDA-targeted TRD positioning.

TypeDirect peer
Description

Clinical-stage biopharma with CNS/sleep programs including orexin-targeting assets. Comparable as a similarly staged, neuroscience-focused peer developing NCEs against validated CNS mechanisms — closely aligned to XWPharma's discovery strategy.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors8 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

XWPharma

Clinical-stage CNS biopharmaceuticalsxwpharma.com

XWPharma is a clinical-stage biopharmaceutical company developing orally bioavailable new chemical entities for sleep and neuropsychiatric CNS disorders, including valiloxybate for narcolepsy and XW10508 for depression and chronic pain, monetizing through licensing deals with pharmaceutical partners.

What XWPharma does

XWPharma is a clinical-stage biopharmaceutical company founded in 2014 that develops new chemical entities (NCEs) targeting central nervous system disorders, with a focus on sleep and neuropsychiatric conditions. The company applies a proprietary medicinal chemistry platform centered on time-regulated neurobiology to design orally bioavailable, once-daily or once-nightly therapies that aim to retain the efficacy of validated mechanisms while addressing the tolerability, dosing, or formulation limitations of existing treatments. Its clinical pipeline includes valiloxybate (XW10172), an internally discovered GABAB agonist conjugate of oxybate being developed for narcolepsy and sleep disorders in Parkinson's disease (FDA Orphan Drug Designation granted in 2019), and XW10508, an oral once-daily glutamatergic NMDA antagonist/AMPA activator derived from esketamine for treatment-resistant major depressive disorder and chronic pain. XWPharma operates leanly from a Redwood City, California headquarters with additional offices in Wuhan, China and New Taipei City, Taiwan, and has raised approximately $80.5 million across three venture rounds from investors including KPCB China, Elements Capital, WI Harper, Panacea Venture, J&J Innovation, and WuXi AppTec.

XWPharma's business model is a clinical-stage licensing model: it discovers and develops drug candidates through early clinical milestones, then out-licenses global development and commercialization rights to pharmaceutical partners in exchange for upfront payments, development and sales milestones, and tiered royalties. The company does not maintain a commercial sales force, and its revenue is structurally tied to licensing economics rather than product sales. In September 2025, XWPharma executed its most significant commercial transaction to date — an exclusive global license to Avadel Pharmaceuticals for valiloxybate, generating a $20 million upfront payment plus up to $185 million in potential milestones and tiered royalties on net sales. Prior to this, the company had been funded exclusively through venture capital. Its customer base is therefore enterprise pharmaceutical partners rather than end patients, prescribers, or payers.

XWPharma firmographics

Firmographics
Name
XWPharma
Legal name
XWPharma Ltd.
Website
https://xwpharma.com
Company type
Private
Founded year
2014
Operating status
Operating
Headcount range
11–50 employees
Short description
XWPharma is a clinical-stage biopharmaceutical company developing orally bioavailable new chemical entities for sleep and neuropsychiatric CNS disorders, including valiloxybate for narcolepsy and XW10508 for depression and chronic pain, monetizing through licensing deals with pharmaceutical partners.
Ownership category
akta.pro rank

XWPharma industry classification

Industry
Product category
Clinical-stage CNS biopharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals

Keywords

  • Clinical-stage biopharmaceutical
  • CNS drug discovery
  • Neurology therapeutics pipeline
  • New chemical entities
  • Pharmaceutical licensing deals

Where XWPharma is headquartered

Location

Headquarters

HQ city
Redwood City
HQ country
United States
HQ region
North America

Offices3 records

Markets served

XWPharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Licensing and milestone payments: XWPharma generates revenue through licensing agreements where partners develop and commercialize its drug candidates. The company receives upfront payments, development milestones, performance-based sales milestones, and tiered royalties. For valiloxybate, Avadel paid $20M upfront with potential for up to $30M in development milestones, up to $155M in sales milestones for net sales up to $750M, plus royalties.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

XWPharma product offering

Product offering

Core offering

XWPharma is a clinical-stage biopharmaceutical company that internally discovers and develops novel small-molecule new chemical entities (NCEs) for central nervous system (CNS) disorders, including Valiloxybate/XW10172 (a GABAB agonist for narcolepsy and Parkinson's disease sleep disorders) and XW10508 (an orally bioavailable NMDA antagonist/AMPA activator for treatment-resistant major depressive disorder and chronic pain). The company advances these programs through early clinical development and licenses them to large pharmaceutical partners (e.g., Avadel Pharmaceuticals) for late-stage development, regulatory approval, and commercialization in exchange for upfront payments, milestones, and royalties.

Product overview

XWPharma is a clinical-stage biopharmaceutical company developing a pipeline of novel CNS drug candidates. The company operates a multi-product portfolio approach with two internally discovered new chemical entities: XW10172 (GABAB agonist for narcolepsy and Parkinson's disease sleep disorders) and XW10508 (NMDA antagonist/AMPA activator for depression and chronic pain). A third candidate, Valiloxybate, was licensed to Avadel Pharmaceuticals in September 2025. All therapies apply novel platform chemistry to time-regulated neurobiology.

Differentiator

Problem solved

Functional benefit

Products and services

  • Valiloxybate (XW10172 / XWL-008) Internally discovered, investigational GABAB agonist new chemical entity (NCE) developed for the treatment of narcolepsy and non-motor symptoms (sleep disorders) in Parkinson's disease. Valiloxybate is a novel, patented conjugate of oxybate designed for once-at-bedtime dosing with optimal pharmacokinetics — rapid oral absorption, prompt release, and sustained duration at desired plasma concentrations. It is salt-free and artificial sweetener-free, addressing formulation limitations of existing oxybate therapies. Granted FDA Orphan Drug Designation in June 2019 for narcolepsy.
  • XW10508 Internally discovered, investigational, orally bioavailable, once-daily glutamatergic new chemical entity providing NMDA receptor inhibition and AMPA receptor activation. Derived from esketamine with extended-release oral formulation, designed to deliver esketamine-like efficacy for treatment-resistant major depressive disorder (MDD) and chronic pain without the transient side effects and administration burden of intranasal or IV esketamine/ketamine.

Companies that use XWPharma

Customer profile

Segments2 records

Ideal customer profiles1 record

XWPharma technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

XWPharma partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Avadel PharmaceuticalsflagshipStrategic or Co-development Partner · 3 September 2025Exclusive global license agreement where Avadel obtained rights to develop and commercialize valiloxybate, a once-at-bedtime, salt-free and artificial sweetener-free oxybate therapy for treating narcolepsy and idiopathic hypersomnia. XWPharma received $20 million upfront payment with potential development milestones up to $30 million, performance-based sales milestones up to $155 million for net sales up to $750 million, and tiered royalties.

Scale indicators10 records

Recent moves6 records

Expansion highlights5 records

XWPharma competitors and assessment

Company assessment

Direct peers

  • Jazz Pharmaceuticals: Markets Xywav (oxybate) and other narcolepsy therapies, generating the bulk of the ~$2B U.S. GABAB narcolepsy market. Directly competes with XWPharma's valiloxybate on mechanism (GABAB agonism) and indication (narcolepsy).
  • Avadel Pharmaceuticals: Exclusive global licensee of XWPharma's valiloxybate (September 2025) and developer of Lumryz, an oxybate therapy for narcolepsy. Directly comparable as a narcolepsy-focused commercial-stage peer with overlapping GABAB asset and patient population.
  • Harmony Biosciences: Markets Wakix (pitolisant) for narcolepsy and is expanding its CNS pipeline. Comparable as a CNS-focused, U.S.-based biopharma targeting narcolepsy patients — the same primary indication as XWPharma's lead asset.
  • Axsome Therapeutics: Commercial CNS company behind Auvelity for major depressive disorder. Closely comparable to XWPharma's XW10508 in target indication (MDD) and strategy of developing differentiated, mechanism-validated CNS therapies.
  • Sage Therapeutics: CNS-focused biopharma that developed Zurzuvae for postpartum depression and has additional CNS programs. Comparable in focus on CNS indications with high unmet need and use of differentiated neuroactive mechanisms, similar to XWPharma's platform approach.
  • Intra-Cellular Therapies: Develops and commercializes Caplyta for CNS indications including schizophrenia and bipolar depression. Directly comparable as a CNS biopharma addressing neuropsychiatric disorders, now operating under Johnson & Johnson following acquisition.
  • Acadia Pharmaceuticals: Markets Nuplazid for Parkinson's disease psychosis and is expanding CNS indications. Directly comparable to XWPharma in CNS focus and overlap on Parkinson's-related indications (XWPharma targets sleep disorders in Parkinson's).
  • BioXcel Therapeutics: Clinical-stage CNS biopharma developing therapies for agitation in dementia and other neuropsychiatric conditions. Comparable as a small, clinical-stage CNS peer pursuing differentiated mechanisms in underserved indications.
  • Centessa Pharmaceuticals: Clinical-stage biopharma with CNS/sleep programs including orexin-targeting assets. Comparable as a similarly staged, neuroscience-focused peer developing NCEs against validated CNS mechanisms — closely aligned to XWPharma's discovery strategy.

Broad incumbents

  • Johnson & Johnson (Janssen): Markets Spravato (esketamine) for treatment-resistant depression, directly competing with XWPharma's XW10508. As a diversified pharma incumbent, J&J is a broader peer but the most relevant comparator for XW10508's NMDA-targeted TRD positioning.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

XWPharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

XWPharma leadership team

Management profile

Number of profiles

Profiles10 records

XWPharma funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

XWPharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about XWPharma

What does XWPharma do?

XWPharma is a clinical-stage biopharmaceutical company that internally discovers and develops novel small-molecule new chemical entities (NCEs) for central nervous system (CNS) disorders, including Valiloxybate/XW10172 (a GABAB agonist for narcolepsy and Parkinson's disease sleep disorders) and XW10508 (an orally bioavailable NMDA antagonist/AMPA activator for treatment-resistant major depressive disorder and chronic pain). The company advances these programs through early clinical development and licenses them to large pharmaceutical partners (e.g., Avadel Pharmaceuticals) for late-stage development, regulatory approval, and commercialization in exchange for upfront payments, milestones, and royalties.

Is XWPharma a public or private company?

XWPharma is a private company. It is classified as venture growth investor backed and is currently operating.

When was XWPharma founded?

XWPharma was founded in 2014. It employs 11 to 50 people.

Where is XWPharma based?

XWPharma is headquartered in Redwood City, United States, in the North America region.

How does XWPharma make money?

One revenue line is on record: licensing and milestone payments.

Who are XWPharma's main competitors?

Direct peers on record are Jazz Pharmaceuticals, Avadel Pharmaceuticals, Harmony Biosciences, Axsome Therapeutics, Sage Therapeutics, Intra-Cellular Therapies, Acadia Pharmaceuticals, BioXcel Therapeutics and Centessa Pharmaceuticals. Johnson & Johnson (Janssen) is listed as a broad incumbent.

Does XWPharma have an API?

No public API is recorded for XWPharma.

What industry is XWPharma in?

XWPharma's product category is Clinical-stage CNS biopharmaceuticals. Its primary akta.pro industry code is HLAIAAAF, Neurology & Psychiatry (CNS) Pharmaceuticals, with a secondary code of HLAIACAC, Neurology & CNS Specialty Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireAvadel Pharmaceuticals Strengthens Sleep Medicine Portfolio with Exclusive License of Valiloxybate from XWPharma LtdAvadel Pharmaceuticals entered an exclusive global license agreement with XWPharma to develop and commercialize valiloxybate, a once-at-bedtime oxybate for narcolepsy and idiopathic hypersomnia. XWPharma will receive $20 million upfront, with potential milestones up to $30 million and sales milestones up to $155 million. Initial PK studies are planned for Q4 2025, with a pivotal trial in H2 2026.Stock TitanAvadel Licenses Valiloxybate Sleep Drug from XWPharma for $20MAvadel Pharmaceuticals entered into an exclusive global license agreement with XWPharma to develop and commercialize valiloxybate, a once-at-bedtime, salt-free and artificial sweetener-free oxybate therapy for treating narcolepsy and idiopathic hypersomnia. XWPharma will receive a $20 million upfront payment, with potential development milestones of up to $30 million, performance-based sales milestones of up to $155 million for net sales up to $750 million, and tiered royalties. Avadel plans to initiate an initial pharmacokinetic study in Q4 2025 followed by a pivotal PK trial in H2 2026, with the possibility of establishing bioequivalence to its existing drug LUMRYZ.GlobeNewswireXWPharma Initiates First-in-Human Studies of XW10508, in Development for Fast-acting Relief of Treatment-Resistant Depression and Chronic PainXWPharma began dosing subjects in its first-in-human Phase 1 study of XW10508, an oral esketamine analog for treatment-resistant depression and chronic pain. The study assesses safety, tolerability, and pharmacokinetics in healthy subjects, with initial results expected in early 2022.GlobeNewswireXWPharma Names Glen Giovannetti to Board of DirectorsXWPharma appointed Glen Giovannetti to its Board of Directors. Giovannetti retired after a 36-year career at Ernst & Young as Senior Partner and Global Life Sciences Sector Leader. He will bring experience in biotech and corporate development to the company.https://www.avcj.comPanacea leads $40m Series C for China's XWPharmaPanacea Venture led a $40 million Series C round for China's XWPharma, a neurobiology-focused biotech. The round brings total funding to $63 million, with new investors including CDIB Capital, Hontai Capital, and Trinity Fund. XWPharma's lead program targets narcolepsy and Parkinson's disease.GlobeNewswireXWPharma Announces $40 Million Financing and Appoints Leonard Blum as Chief Executive OfficerXWPharma completed a $40 million Series C financing led by Panacea Venture, with participation from existing and new investors. The company will use proceeds to advance clinical development of its lead programs XW10172 and XW10508, and appointed Leonard Blum as CEO, succeeding Jia-Ning Xiang as founder and chairman.